Company Snapshot: KemPharm, Inc.

KMPH
Last	Change	Volume	High	Low

Company Overview

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. Its product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. The company also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. It has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ. The company was founded in 2006 and is headquartered in Celebration, Florida.

Client News

1. Jan 24 2023 KemPharm Issues Letter to Shareholders
2. Jan 18 2023 KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy
3. Jan 11 2023 KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer
4. Jan 9 2023 KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company